Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer

Breast Cancer Clinical Trial

Official title:

Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03080155
• Other study ID #: 960-CLP-GER_Multimodality_GER1
• Status: Recruiting
• Phase: N/A
• Start date: September 2016
• Est. completion date: October 2018

Study information

• Verified date: June 2018
• Source: Real Imaging Ltd.
• Contact: David Izhaky
• Phone: +972-3-972-0602
• Email: David[@]realimaging.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to assess the effectiveness of MIRA in classifying women with dense breast tissue for supplemental breast MRI. To assess the effectiveness of MIRA for correctly classifying women with breast cancer and to evaluate the safety of the device.

In women above 30 years old who are undergoing MRI or are scheduled for image-guided needle biopsy due to lesions detected by other imaging modalities.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 680
• Est. completion date: October 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 30 Years to 79 Years

Eligibility

Inclusion Criteria:

• Women who are between 30 to 70 years of age and who are asymptomatic and scheduled to undergo routine breast cancer screening (MRI and/or mammography) OR

• Women who are between 30 to 79 years of age and scheduled for image-guided needle biopsy as a result of findings obtained during standard of care imaging modalities (mammography, ultrasound and/or MRI) performed at the clinical site that participates in the study.

Exclusion Criteria:

1. Contraindication to bilateral mammography or MRI.

2. Subjects who are unable to read, understand and execute the informed consent procedure.

3. Subjects who have had mammography, ultrasound or MRI examination performed on the day of the study prior to MIRA scan.

4. Subjects who have significant existing breast trauma.

5. Subjects who have undergone lumpectomy/mastectomy.

6. Subjects who have undergone breast reduction or breast augmentation.

7. Subjects who have undergone any other type of breast surgery.

8. Subjects who have large breast scar / Breast deformation.

9. Subjects who have undergone a breast needle biopsy within the 6-month period prior to their intended enrollment into the study.

10. Subjects who have a temperature > 37.8C degrees on the day of the MIRA imaging.

11. Subjects who are pregnant or lactating.

12. Subjects who have had placement of an internal breast marker.

13. Subjects with known Raynaud's Disease.

14. Subjects that are claustrophobic or have physical limitations that do not allow them to sit in the system chair for the required imaging session.

15. Subjects with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices.

16. Inmates or mentally disabled individuals.

17. Subjects with a BI-RADS category 6 (e.g. for which mammogram was performed for the purpose of planning cancer therapy).

18. Subjects who participated in the Calibration Phase will not be able to participate in the Testing Phase.

19. Subjects currently participating in another investigational clinical study.

20. Subjects undergoing breast MR for pre-staging.

21. Subjects with known Mastitis

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Device:
• MIRA device imaging
MIRA Device imaging for adjunctive detection of breast cancer

Locations

Country	Name	City	State
Germany	BrustZentrum	Göttingen

Sponsors (1)

Lead Sponsor	Collaborator
Real Imaging Ltd.

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	determining MIRA's PPV (positive predictive value)	The positive predictive value (and the amount of false-positive diagnoses) of MIRA will be determined using positive MRI (MRI BI-RADS >= 3) as a reference test in cohort of women with negative (Mammography BI-RADS 1 or 2).; The positive predictive value (and the amount of false-positive diagnoses) of MIRA will be determined using the histological diagnosis as the reference test in ALL women participated in the study.	24 months